Toll Free: 1-888-928-9744

Hepatocellular Carcinoma Global Clinical Trials Review, H1, 2016

Published: May 31, 2016 | Pages: 1047 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hepatocellular Carcinoma Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Hepatocellular Carcinoma Global Clinical Trials Review, H1, 2016" provides an overview of Hepatocellular Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatocellular Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Report Guidance 6 Clinical Trials by Region 7 Clinical Trials and Average Enrollment by Country 8 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10 Top Five Countries Contributing to Clinical Trials in Europe 11 Top Countries Contributing to Clinical Trials in North America 12 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13 Top Five Countries Contributing to Clinical Trials in Central and South America 14 Clinical Trials by G7 Countries: Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials 15 Clinical Trials by Phase in G7 Countries 16 Clinical Trials in G7 Countries by Trial Status 17 Clinical Trials by E7 Countries: Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials 18 Clinical Trials by Phase in E7 Countries 19 Clinical Trials in E7 Countries by Trial Status 20 Clinical Trials by Phase 21 In Progress Trials by Phase 22 Clinical Trials by Trial Status 23 Clinical Trials by End Point Status 24 Subjects Recruited Over a Period of Time 25 Clinical Trials by Sponsor Type 26 Prominent Sponsors 27 Top Companies Participating in Hepatocellular Carcinoma Therapeutics Clinical Trials 28 Prominent Drugs 29 Latest Clinical Trials News on Hepatocellular Carcinoma 30 May 19, 2016: Incyte Highlights Capmatinib Abstracts to be Presented at the 2016 ASCO Annual Meeting 30 May 18, 2016: Eli Lilly to Present data on VEGF Receptor 2 antagonist ramucirumab at ASCO 30 May 18, 2016: Lilly to present data on TGF small-molecule kinase inhibitor galunisertib at ASCO 31 May 12, 2016: CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC) 32 May 04, 2016: RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA Phase II Hepatocellular Carcinoma Study 32 May 04, 2016: Phase III Trial of Regorafenib in Patients with Unresectable Liver Cancer Meets Primary Endpoint of Improving Overall Survival 33 Apr 26, 2016: Celsion Announces Enrollment of First Patient in the OPTIMA Study in China 34 Apr 18, 2016: Onxeo Final Data from Mechanistic Livatag Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment 35 Apr 15, 2016: Conatus Poster at EASL Meeting Today Addresses Safety of Caspase Inhibition in Cancer Treatment 35 Apr 04, 2016: Onxeo announces positive DSMB recommendation to continue Livatag ReLive study in HCC 36 Mar 29, 2016: SillaJen Enrolls First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer 36 Mar 22, 2016: Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma 37 Mar 16, 2016: Onxeo Poster Demonstrating Unique Livatag Mechanism of Action Accepted for Presentation at AACR Annual Meeting 37 Mar 07, 2016: Major Liver Cancer Study Completes Palliative Cohort Enrolment 38 Mar 07, 2016: Celsion Announces Launch of the OPTIMA Study in China 38 Clinical Trial Profile Snapshots 40 Appendix 1044 Abbreviations 1044 Definitions 1044 Research Methodology 1045 Secondary Research 1045 About GlobalData 1046 Contact Us 1046 Disclaimer 1046 Source 1047
List of Tables
Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Region, 2016* 7 Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8 Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Hepatocellular Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10 Hepatocellular Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11 Hepatocellular Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2016* 12 Hepatocellular Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13 Hepatocellular Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14 Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2016* 15 Hepatocellular Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16 Hepatocellular Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17 Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2016* 18 Hepatocellular Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19 Hepatocellular Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20 Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2016* 21 Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22 Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23 Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24 Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25 Hepatocellular Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26 Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27 Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28 Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29


List of Figures
Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 7 Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8 Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9 Hepatocellular Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10 Hepatocellular Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11 Hepatocellular Carcinoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12 Hepatocellular Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13 Hepatocellular Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14 Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2016* 15 Hepatocellular Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16 Hepatocellular Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17 Proportion of Hepatocellular Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2016* 18 Hepatocellular Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19 Hepatocellular Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20 Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21 Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22 Hepatocellular Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23 Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24 Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25 Hepatocellular Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26 Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27 Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28 Hepatocellular Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29 GlobalData Methodology 1045

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing i

Read More...

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...

Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. Increasin

Read More...

Global heat transfer fluids market size is likely to be valued at USD 3.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing demand for for heat recovery management in industries such as metal processing, pharmaceutica

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify